EUVIMEDEUVIMED entdecken
Crossref

Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1764) · e79-e80

DOI: 10.58347/tml.2026.1754f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relacorilant (Lifyorli – Corcept Therapeutics), an oral first-in-class glucocorticoid receptor antagonist, has been approved by the FDA for use in combination with nab-paclitaxel (Abraxane, and generics) for treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy, one of which included bevacizumab (Avastin, and others).

Schlagwörter

Stichwörter der Autor:innen

AbraxaneAvastinLifyorliadverse effectsbevacizumabdosagedrug interactionsefficacylactationovarian cancerpaclitaxelpregnancyrelacorilantsafety

Zitieren

APA

(2026). Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Medical Letter on Drugs and Therapeutics, 68(1764), e79-e80. https://doi.org/10.58347/tml.2026.1754f

Vancouver

Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. The Medical Letter on Drugs and Therapeutics. 2026;68(1764):e79-e80. doi:10.58347/tml.2026.1754f

BibTeX
@article{euvimed2026,
  title = {Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1764},
  pages = {e79--e80},
  doi = {10.58347/tml.2026.1754f}
}
Kostenlos starten →